Literature DB >> 7114839

Comparative activities of 13 beta-lactam antibiotics.

H L Muytjens, J van der Ros-van de Repe.   

Abstract

An agar dilution method was used to measure the minimal inhibitory concentrations of 13 beta-lactam antibiotics against 868 recent human clinical isolates. Most members of the Enterobacteriaceae were susceptible to cefoperazone, ceftazidime, moxalactam, N-formimidoyl thienamycin, ceftriaxone, and ceftizoxime. Cephalothin was the most active antibiotic against Staphylococcus aureus. Most strains of Pseudomonas aeruginosa were inhibited by ceftazidime, N-formimidoyl thienamycin, and cefsulodin. N-Formimidoyl thienamycin was active against all of the species tested.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7114839      PMCID: PMC182047          DOI: 10.1128/AAC.21.6.925

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  Comparative in vitro activity of moxalactam, cefotaxime, cefoperazone, piperacillin, and aminoglycosides against gram-negative bacilli.

Authors:  T O Kurtz; D J Winston; J A Hindler; L S Young; W L Hewitt; W J Martin
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

2.  N-formimidoyl-thienamycin a novel beta-lactam: an in-vitro comparison with other beta-lactam antibiotics.

Authors:  R Wise; J M Andrews; N Patel
Journal:  J Antimicrob Chemother       Date:  1981-05       Impact factor: 5.790

3.  Comparative activities of the oxa-beta-lactam LY127935, cefotaxime, cefoperazone, cefamandole, and ticarcillin against multiply resistant gram-negative bacilli.

Authors:  W H Hall; B J Opfer; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

4.  Comparison of activity and beta-lactamase stability of cefotaxime with those of six other cephalosporins.

Authors:  R P Mouton; G P Bongaerts; M van Gestel
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

5.  Comparative in vitro activities of cefotaxime and ceftizoxime (FK749): new cephalosporins with exceptional potency.

Authors:  D Greenwood; N Pearson; A Eley; F O'Grady
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

6.  In vitro evaluation of cefoperazone.

Authors:  A M Hinkle; B M LeBlanc; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

7.  Antibacterial activity of ceftizoxime, a beta-lactamase-stable cephalosporin.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

8.  In vitro activity of N-formimidoyl thienamycin (MK0787).

Authors:  F P Tally; N V Jacobus; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

9.  Antibacterial activities of a new stabilized thienamycin, N-formimidoyl thienamycin, in comparison with other antibiotics.

Authors:  T Kesado; T Hashizume; Y Asahi
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

10.  GR-20263: a new aminothiazolyl cephalosporin with high activity against Pseudomonas and Enterobacteriaceae.

Authors:  L Verbist; J Verhaegen
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

View more
  41 in total

1.  Comparison of genomic DNAs of different enterococcal isolates using restriction endonucleases with infrequent recognition sites.

Authors:  B E Murray; K V Singh; J D Heath; B R Sharma; G M Weinstock
Journal:  J Clin Microbiol       Date:  1990-09       Impact factor: 5.948

2.  Therapeutic effects of cefpirome (HR 810) on experimental mixed infections with Enterococcus faecalis and Escherichia coli in mice.

Authors:  S Arai; S Hayashi
Journal:  Infection       Date:  1990 May-Jun       Impact factor: 3.553

3.  Comparison of in vitro antibiograms of Bacteroides fragilis group isolates: differences in resistance rates in two institutions because of differences in susceptibility testing methodology.

Authors:  K E Aldridge; H M Wexler; C V Sanders; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

4.  Comparison of ceftazidime with cefamandole for therapy of community-acquired pneumonia.

Authors:  J C Engle; P W Lifland; C J Schleupner
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

5.  Clinical experience with cefotaxime for the therapy of bacteremias due to gram-positive organisms.

Authors:  C J Schleupner
Journal:  Infection       Date:  1985       Impact factor: 3.553

Review 6.  In vitro activity of imipenem--a review.

Authors:  I Braveny
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

7.  Dosage adjustment for ceftazidime in patients with impaired renal function.

Authors:  R van Dalen; T B Vree; A M Baars; E Termond
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Ceftizoxime (FK 749) in vitro antibacterial activity.

Authors:  M O Husson; R Courcol; D Izard; H Leclerc
Journal:  Infection       Date:  1984 Jan-Feb       Impact factor: 3.553

Review 9.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

Review 10.  Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  S P Clissold; P A Todd; D M Campoli-Richards
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.